Eolo Pharma focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases.
Eolo Pharma has raised $1.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2023.
Eolo Pharma's investors include Ficus Capital, Cites.
Eolo Pharma is headquartered in Wilmington, United States.
Eolo Pharma focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases.
Eolo Pharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eolo Pharma — Funding & Investors." VCBacked, February 8, 2023, https://www.vcbacked.co/company/eolo-pharma. Accessed August 15, 2026.
VCBacked. (2023). Eolo Pharma — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/eolo-pharma
{{cite web |title=Eolo Pharma — Funding & Investors |url=https://www.vcbacked.co/company/eolo-pharma |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated